Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
|Articles|October 1, 2010
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-10-01-2010
- Volume 22
- Issue 10
Quantitative open-access HPLC analysis: a new calibration approach
A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high?performance liquid chromatography without having to prepare standards.
Advertisement
A novel tool enables users to generate reliable data for yields in solution and for assays of isolated solids using high‑performance liquid chromatography without having to prepare standards. The authors discuss the approach taken to develop the tool, its associated protocols and how it can be used to calculate data.
Articles in this issue
about 16 years ago
Validating Single-Use Systemsabout 16 years ago
EGA Position On The EC's Proposal For A Falisifed Medicines Directiveabout 16 years ago
Green is the wordabout 16 years ago
Newsabout 16 years ago
The Pros And Cons Of Single-Use Systemsabout 16 years ago
Europe: A Future Leader in Vaccines?about 16 years ago
Developing A Quality Agreement Template For Single-Use Systemsabout 16 years ago
Online Monitoring Of Continuous Hot Melt Extrusionabout 16 years ago
An All-Round Excipient For Direct CompressionAdvertisement
Related to this article
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
Improving Oral Peptide Delivery Through Structural Modifications
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5